This review article explores the role of microRNAs (miRNAs) in cervical cancer, focusing on their potential as diagnostic biomarkers and therapeutic targets. Cervical cancer is the fourth most common cancer in women, with 604,000 new cases and 342,000 deaths annually. It is primarily caused by Human Papillomavirus (HPV), which induces genetic and epigenetic changes in cervical epithelial cells. While genetic mutations are well-studied, epigenetic changes, including miRNA dysregulation, are increasingly recognized as important in cervical cancer progression. MiRNAs are small non-coding RNA molecules that regulate gene expression by binding to messenger RNA (mRNA). They play crucial roles in cancer development, progression, and metastasis. The review discusses the biogenesis of miRNAs, their regulation by HPV oncoproteins (E5, E6, E7), and their involvement in various signaling pathways such as PI3K/AKT, Wnt/β-catenin, and JAK/STAT. MiRNA dysregulation is linked to changes in gene expression, DNA methylation, and histone modifications, which contribute to cervical cancer progression. The article highlights the use of miRNAs as biomarkers for cervical cancer diagnosis, particularly in serum and cervical cells. It also discusses their potential in therapeutic applications, including miRNA-based therapies and immunotherapy. The review emphasizes the importance of miRNAs in drug resistance and the role of the tumor microenvironment in miRNA regulation. Overall, the study suggests that miRNAs could serve as valuable tools for early detection, prognosis, and targeted therapy in cervical cancer.This review article explores the role of microRNAs (miRNAs) in cervical cancer, focusing on their potential as diagnostic biomarkers and therapeutic targets. Cervical cancer is the fourth most common cancer in women, with 604,000 new cases and 342,000 deaths annually. It is primarily caused by Human Papillomavirus (HPV), which induces genetic and epigenetic changes in cervical epithelial cells. While genetic mutations are well-studied, epigenetic changes, including miRNA dysregulation, are increasingly recognized as important in cervical cancer progression. MiRNAs are small non-coding RNA molecules that regulate gene expression by binding to messenger RNA (mRNA). They play crucial roles in cancer development, progression, and metastasis. The review discusses the biogenesis of miRNAs, their regulation by HPV oncoproteins (E5, E6, E7), and their involvement in various signaling pathways such as PI3K/AKT, Wnt/β-catenin, and JAK/STAT. MiRNA dysregulation is linked to changes in gene expression, DNA methylation, and histone modifications, which contribute to cervical cancer progression. The article highlights the use of miRNAs as biomarkers for cervical cancer diagnosis, particularly in serum and cervical cells. It also discusses their potential in therapeutic applications, including miRNA-based therapies and immunotherapy. The review emphasizes the importance of miRNAs in drug resistance and the role of the tumor microenvironment in miRNA regulation. Overall, the study suggests that miRNAs could serve as valuable tools for early detection, prognosis, and targeted therapy in cervical cancer.